Findings

What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Intervention not reported

Change of hepatocellular enzymes1 · adults and children with cystic fibrosis‐related liver disease

1 finding from 1 review

Ursodeoxycholic acid for cystic fibrosis‐related liver disease 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 16 participants
Very low

Intervention not reported

Abnormally large livers reduced to within normal limits, as measured by ultrasound · adults and children with cystic fibrosis‐related liver disease

The review found no eligible studies for this question.

1 finding from 1 review

Ursodeoxycholic acid for cystic fibrosis‐related liver disease 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Need for liver transplantation · adults and children with cystic fibrosis‐related liver disease

1 finding from 1 review

Ursodeoxycholic acid for cystic fibrosis‐related liver disease 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 58 participants
Very low

Intervention not reported

Mortality · adults and children with cystic fibrosis‐related liver disease

1 finding from 1 review

Ursodeoxycholic acid for cystic fibrosis‐related liver disease 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 58 participants
Low

Intervention not reported

Nutritional status: change in weight (kg) · adults and children with cystic fibrosis‐related liver disease

1 finding from 1 review

Ursodeoxycholic acid for cystic fibrosis‐related liver disease 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 30 participants
Low

Intervention not reported

Development of portal hypertension · adults and children with cystic fibrosis‐related liver disease

1 finding from 1 review

Ursodeoxycholic acid for cystic fibrosis‐related liver disease 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 30 participants
Low

Intervention not reported

Improved abnormal biliary excretion · adults and children with cystic fibrosis‐related liver disease

1 finding from 1 review

Ursodeoxycholic acid for cystic fibrosis‐related liver disease 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Low

Intervention not reported

Change in weight (kg):1 at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Moderate

Intervention not reported

Change in height (cm):1 at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Moderate

Intervention not reported

Change in total calories (Kcal/day): at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Intervention not reported

Change in total protein (g/day): at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Intervention not reported

Change in total fat (g/day): at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Intervention not reported

Adverse events: · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Intervention not reported

Change in lung function ‐ FEV₁ (% predicted): at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Deferasirox vs deferoxamine

Mortality at any time point · people with transfusion‐dependent thalassemia

Deferasirox showed no clear difference in mortality at any time point compared with deferoxamine (low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 0.48 [0.09, 2.63]
8 studies · 1170 participants
Low

Deferasirox vs deferiprone

Serum ferritin (ng/mL): mean change from baseline and at end of study · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 83 participants
Very low

Deferasirox vs deferiprone

LIC · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

Deferasirox vs deferiprone

Satisfaction · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs deferiprone

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

Deferasirox showed no clear difference in adherence: discontinuations compared with deferiprone (low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 0.16 [0.01, 2.99]
3 studies · 179 participants
Low

Deferasirox vs deferiprone

Renal failure · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Very low